GRAIL is trading at $131.57, down 4.16%, amid broad market and biotech-sector weakness.
- No clear negative company-specific catalyst has surfaced; the recent announcement concerned upcoming research presentations, not adverse results.
- Investors are cautious as Treasury yields and oil prices rise ahead of Federal Reserve minutes. The supplied sector context shows XBI down 2.50%.